Product Details
| Product Name:
Rentiapril racemate |
CAS No.:
72679-47-1 |
| Purity:
98.96% |
Supply Ability:
10g |
| Release date:
2024/11/20 |
Product Introduction
Bioactivity
| Name | Rentiapril racemate |
| Description | Rentiapril racemate (SA-446 racemate) is the racemic form of Rentiapril, exhibiting anti-inflammatory properties and potential applications in glaucoma research. |
| In vivo | A three-month toxicity study of Rentiapril (CAS 80830-42-8), an angiotensin-converting enzyme (ACE) inhibitor, is conducted in Sprague-Dawley rats through oral administration. Dose levels of 0, 30, 125, 500, and 1000 mg/kg are tested in both sexes, with each experimental group consisting of 10 rats. Captopril, another ACE inhibitor, is used as a reference compound.At the highest dose of 1000 mg/kg, Rentiapril causes low food consumption and death in some animals, presenting signs of bloody feces and anemia. In males and females receiving 500 and 1000 mg/kg, there are low body weight gain, increases in water intake, urine volume, and serum BUN level, and decreases in various erythrocytic parameters. Kidney weight increases dose-dependently in both sexes. Histopathologically, renal changes in the 500 and 1000 mg/kg groups consist of proximal tubular degeneration, juxtaglomerular cell hyperplasia, and interstitial cell infiltration. Similar but milder changes in proximal tubules are present in the female 125 mg/kg group. Dead animals from the highest dose groups further show gastrointestinal hemorrhagic erosion and/or ulcer, decreased bone marrow erythropoiesis, and hepatocytic vacuolar degeneration. No pathological alterations are observed in rats from other Rentiapril-treated groups or in controls. These results indicate that the no-effect dose of Rentiapril in rats, following three months of oral administration, is 30 mg/kg in females and 125 mg/kg in males[1]. |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (159.55 mM), Sonication is recommended.
|
| Keywords | Rentiapril racemate |
| Inhibitors Related | H-Ile-Pro-Pro-OH acetate | Temocaprilat | Tuna AI acetate | Trandolapril | Palatrigine | Libenzapril | N-Hippuryl-His-Leu hydrate | Zabicipril HCl | L-Isoleucyl-L-arginine | Vicenin-1 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:851599-82-1
$165.00 / 1mg
-
CAS:1038915-75-1
$45.00 / 1mg
-
CAS:186543-64-6
$38.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$297.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
United States